| 生物活性 |
(1S,9R)-Exatecan mesylate ((1S,9R)-DX8951f) is a non-prodrug camptothecin derivative that acts as a topoisomerase I inhibitor (IC50=0.975 μg/mL in mouse and 0.82 μg/mL in human), blocking enzyme activity and inducing apoptosis (apoptosis) by stabilizing the enzyme-DNA cleavable complex; it not only effectively inhibits the proliferation and tumor growth of various malignant tumor cells but also circumvents P-glycoprotein-mediated multidrug resistance, and is therefore widely used in preclinical studies of various cancers such as pancreatic cancer, lung cancer, breast cancer, and leukemia, with its chiral isomer being (1R,9R)-Exatecan mesylate (MS-H96188). |
体外研究 (In Vitro) |
(1S,9R)-Exatecan (mesylate) (48 h exposure; additional 5 days culture post-exposure) 及其盐酸盐形式 DX-8951a 可在体外强效抑制 SUIT-2、KP-1N、SUIT-2/CPT-11 和 KP-1N/CPT-11 人胰腺癌细胞的生长,IC50 值为 0.079 至 0.69 ng/mL;与其他喜树碱类似物相比,其在 CPT-11 耐药细胞系中的交叉耐药性更低。 (1S,9R)-Exatecan (mesylate) (0.16-10 μg/mL; 10 min at 37°C) (tested as DX-8951a) 可抑制 SUIT-2 人胰腺癌细胞中的拓扑异构酶 I 活性,其 IC50 为 0.82 μg/mL,抑制效力比 SN-38 强 2.8 倍。 (1S,9R)-Exatecan (mesylate) (0.8-500 ng/mL; 24 h) (以 DX-8951a 形式测试) 可剂量依赖性地诱导人胰腺癌细胞系 SUIT-2 发生 DNA 片段化 (细胞凋亡的标志物),20 ng/mL 作用 24 h 后可观察到 60% 的片段化,且其活性强于 SN-38。 (1S,9R)-Exatecan (mesylate) (0.05 μg/mL; 24 h) (tested as DX-8951a) 可在 SUIT-2 人胰腺癌细胞中诱导凋亡性细胞死亡的形态学特征,包括染色质浓缩、核碎裂和细胞质空泡化。 (1S,9R)-Exatecan (mesylate) (Doses yielding GI50 values; 3 days post-drug addition) 可强效抑制 31 种人类癌细胞系及小鼠白血病 P388 细胞的增殖,总体平均 GI50 为 2.09 ng/mL,且效力优于对比化合物。 (1S,9R)-Exatecan (mesylate) (Doses yielding IC50 values) 可强效抑制 P388 细胞来源的拓扑异构酶 I 活性,其 IC50 为 0.975 μg/mL,且效力优于对比化合物。 (1S,9R)-Exatecan (mesylate) (Doses yielding GI50 values; 3 days post-drug addition) 对过表达 P-糖蛋白的 PC-6/VCR 细胞仍具有强细胞毒活性,可克服 P-糖蛋白介导的多药耐药性。
Apoptosis Analysis
| Cell Line: |
SUIT-2 |
| Concentration: |
0.8-500 ng/mL |
| Incubation Time: |
24 h |
| Result: |
Induced DNA fragmentation in a dose-dependent manner. Caused approximately 60% DNA fragmentation at 20 ng/mL. Achieved equivalent fragmentation at a 5-times lower concentration than SN-38. |
Cell Cytotoxicity Assay
| Cell Line: |
31 human cancer cell lines (breast, colon, stomach, lung, ovarian, leukemia) and mouse leukemia P388 cells |
| Concentration: |
Doses yielding GI50 values |
| Incubation Time: |
3 days post-drug addition |
| Result: |
Exhibited strong antiproliferative activity with mean GI50 values of 2.02 ng/mL against breast cancer cell lines, 2.92 ng/mL against colon cancer cell lines, 1.53 ng/mL against stomach cancer cell lines, 0.877 ng/mL against lung cancer cell lines, and 4.33 ng/mL against other cell lines including ovarian cancer, human leukemia, and mouse leukemia. Achieved an overall mean GI50 value of 2.09 ng/mL across all 32 cell lines. |
Cell Cytotoxicity Assay
| Cell Line: |
Human non-small cell lung cancer PC-6 cells and its P-glycoprotein-overexpressing variant PC-6/VCR cells |
| Concentration: |
Doses yielding GI50 values; 5 μg/mL verapamil (co-treatment with PC-6/VCR cells) |
| Incubation Time: |
3 days post-drug addition |
| Result: |
Achieved GI50 values of 0.0896 ng/mL for PC-6 cells and 0.0690 ng/mL for PC-6/VCR cells (without verapamil, first set), with a degree of resistance of 0.8. Achieved GI50 values of 0.179 ng/mL for PC-6 cells and 0.182 ng/mL for PC-6/VCR cells (without verapamil, second set), with a degree of resistance of 1.0. Reduced the GI50 value of PC-6/VCR cells to 0.156 ng/mL (with 5 μg/mL verapamil), with a VR (+)/VR (−) ratio of 0.86. |
|
体内研究 (In Vivo) |
(1S,9R)-Exatecan (mesylate) (3.125-18.75 mg/kg; i.v.; every 4 days; 4 doses) 在裸鼠的 SUIT-2 胰腺癌异种移植物模型中,可在较宽剂量范围内产生具有统计学意义的肿瘤生长抑制作用,抑制率为 68% 至 79%,且未出现相关的体重减轻或毒性相关死亡。 (1S,9R)-Exatecan (mesylate) (3.125-18.75 mg/kg; i.v.; every 4 days; 4 doses) 在最大耐受剂量下,对裸鼠体内耐 CPT-11 的 SUIT-2/CPT-11 胰腺癌异种移植物产生 72%的具有统计学意义的肿瘤生长抑制作用,仅出现短暂的体重下降,且无毒性相关死亡。 (1S,9R)-Exatecan (mesylate) (2.5-10 mg/kg; i.v.; every 5 days; 4 doses) 可在裸鼠中对 SUIT-2 胰腺癌的肝转移产生剂量依赖性、具有统计学意义的抑制作用;在最高测试剂量下,肝肿瘤评分抑制率达 78%,且 7 只小鼠中有 3 只无瘤,同时未出现显著的体重下降。 (1S,9R)-Exatecan (mesylate) (3.325-50 mg/kg; i.v.; three doses at 4-day intervals) 对裸鼠体内人胃腺癌 SC-6 异种移植物表现出剂量依赖性的强效抗肿瘤活性;在总静脉注射剂量为 50 mg/kg (three doses at 4-day intervals) 时,其对肿瘤生长的最大体重抑制率达 92%,且未导致动物中毒死亡。
| Animal Model: |
BALB/c-nu/nu (male, 6 weeks old) |
| Dosage: |
3.125 mg/kg (total 12.5 mg/kg); 6.25 mg/kg (total 25 mg/kg); 12.5 mg/kg (total 50 mg/kg); 18.75 mg/kg (total 75 mg/kg) |
| Administration: |
i.v.; every 4 days; 4 doses |
| Result: |
Produced tumor growth inhibition (IR) rates of 68%, 78%, 68%, and 79%, respectively. Resulted in mean tumor weights of 0.235±0.057 g, 0.164±0.053 g, 0.236±0.100 g, and 0.154±0.027 g, respectively. Caused no body weight loss in any treated group, and no mice died of toxicity.\nAt total dose of 75 mg/kg, produced a tumor growth inhibition (IR) rate of 72% with a mean tumor weight of 0.250±0.061 g; caused maximum body weight loss of 14.6% on day 31. At total doses of 50 mg/kg, 25 mg/kg, and 12.5 mg/kg, resulted in IR rates of 33%, 13%, and 20% with mean tumor weights of 0.595±0.130 g, 0.776±0.157 g, and 0.712±0.065 g, respectively; caused maximum body weight loss of 6.1% (day 21), 8.7% (day 15), and 3.2% (day 15), respectively. Caused no mice to die of toxicity in any treated group. |
| Animal Model: |
BALB/c-nu/nu (male, 6 weeks old) |
| Dosage: |
2.5 mg/kg (total 10 mg/kg); 5 mg/kg (total 20 mg/kg); 10 mg/kg (total 40 mg/kg) |
| Administration: |
i.v.; every 5 days; 4 doses |
| Result: |
At total dose of 40 mg/kg, produced a liver tumor growth score inhibition rate of 78%, with a mean liver tumor score of 0.7±0.9, mean liver weight of 1.594±0.154 g, and 3/7 mice with no visible liver tumor nodules; found 2/7 mice with visible spleen tumor nodules, and 0/7 mice with ascites, with 3/7 mice being tumor-free. At total dose of 20 mg/kg, resulted in a liver tumor growth score inhibition rate of 69%, with a mean liver tumor score of 1.0±0.6, mean liver weight of 1.594±0.163 g, 5/6 mice with liver tumor nodules, 2/6 mice with spleen tumor nodules, 0/6 mice with ascites, and 1/6 mice tumor-free. At total dose of 10 mg/kg, resulted in a liver tumor growth score inhibition rate of 28%, with a mean liver tumor score of 2.3±1.1, mean liver weight of 1.780±0.197 g, 6/6 mice with liver tumor nodules, 3/6 mice with spleen tumor nodules, 2/6 mice with ascites (mean volume 0.1±0.1 mL, 97% inhibition), and 0/6 mice tumor-free. Caused no significant body weight loss. |
| Animal Model: |
BALB/c-nu/nu (male, 5 or 6 weeks old, human gastric adenocarcinoma SC-6 cells transplanted s.c.) |
| Dosage: |
3.325 mg/kg; 6.25 mg/kg; 12.5 mg/kg; 25 mg/kg; 50 mg/kg |
| Administration: |
i.v.; three doses at 4-day intervals |
| Result: |
Achieved 54% maximal tumor growth inhibition by volume (day 12) and 43% tumor growth inhibition by weight at total dose 3.325 mg/kg, with 3.8% maximal body weight reduction (day 6) and 0 toxic deaths. Achieved 72% maximal tumor growth inhibition by volume (day 14) and 58% statistically significant tumor growth inhibition by weight at total dose 6.25 mg/kg, with 2.6% maximal body weight reduction (day 6) and 0 toxic deaths. Achieved 82% maximal tumor growth inhibition by volume (day 17) and 73% statistically significant tumor growth inhibition by weight at total dose 12.5 mg/kg, with 5.9% maximal body weight reduction (day 6) and 0 toxic deaths. Achieved 95% maximal tumor growth inhibition by volume (day 17) and 90% statistically significant tumor growth inhibition by weight at total dose 25 mg/kg, with 7.0% maximal body weight reduction (day 6) and 0 toxic deaths. Achieved 96% maximal tumor growth inhibition by volume (day 17) and 92% statistically significant tumor growth inhibition by weight at total dose 50 mg/kg, with 12.5% maximal body weight reduction (day 12) and 0 toxic deaths. |
|